JAC Advance Access published online on July 15, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg339
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Department of Antibiotics, National Veterinary Institute
(SVA), SE- 751 89 Uppsala, Sweden
* Corresponding author. E-mail: christina.greko{at}sva.se.
Received 27 January 2003
; revised 23 May 2003
; accepted 28 May 2003
Objective: To evaluate an experimental
model of the pharmacokinetic/pharmacodynamic (PK/PD) relationship
of danofloxacin against Mannheimia haemolytica infection,
using subcutaneously implanted tissue cages in calves. Methods: Tissue cages implanted subcutaneously
in calves were infected with M. haemolytica and
different concentration-time profiles of danofloxacin were
simulated. Drug concentrations and bacterial counts were monitored
over time and various PK/PD parameters calculated. Results: By using different types of cage and
various doses, a range of PK/PD indices were simulated. The PK/PD
index that best predicted the antimicrobial effect was the AUC/MIC
ratio. The magnitude of this index needed for near-maximum effect
(80%), assessed using the area under the bacterial kill
curve to 48 h, was 244 h. Conclusions: The model described enabled different
concentration-time profiles to be simulated, and
PK/PD interactions to be studied in the presence of the host's
defences. The validity of this model needs to be confirmed by clinical
studies, but the results suggest that it may be a useful intermediary
step between in vitro and clinical studies.
Keywords: pharmacodynamics, in vivo models,
tissue cages, fluoroquinolones, Mannheimia
Pharmacokinetic/pharmacodynamic relationship of
danofloxacin against Mannheimia haemolytica in
a tissue-cage model in calves
![]()
CiteULike
Connotea
Del.icio.us What's this?